TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18661414
Drug: Intravenous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous low molecular weight iron dextran (ID)
Study: 29667099
Drug: Drug discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug discontinuation
Study: 6362699
Drug: Brotizolam 0.25
Normalized name: brotizolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.25 mg
Study: 10030617
Drug: Contrast sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast sensitivity measured with sine-wave grating patches at varying luminance and eccentricity levels.
Study: 2185299
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg glypressin intravenously (i.v.)
Study: 7379678
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution without bile salts
Study: 20636718
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with uric acid (1 g) and rtPA
Study: 16645532
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimicifuga racemosa (CR) 40 mg/day
Study: 16645532
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) 0.6 mg/day
Study: 6762167
Drug: Torasemide 60
Normalized name: torsemide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 60 mg
Study: 6762167
Drug: Furosemide 120
Normalized name: furosemide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 120 mg
Study: 24909293
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg and 10 mg
Study: 23384091
Drug: Rupatadine oral
Normalized name: rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine oral solution (1 mg/ml)
Study: 20939473
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 5000 U/day (high dose group)
Study: 20939473
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) 2500 U/day (low dose group)
Study: 10754612
Drug: Sedative and
Normalized name: Anxiolytic, sedative AND/OR hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative and PPIA group
Study: 10754612
Drug: Sedative group
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative group
Study: 3908125
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg once daily
Study: 3908125
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg twice daily
Study: 3908125
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg/amiloride 5 mg twice daily (HCT/A)
Study: 22658123
Drug: Finasteride 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 0.5% solution applied twice daily
Study: 22658123
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution applied twice daily
Study: 15957830
Drug: Danshen injection
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen injection (DSI) 60 ml once a day for 10 days
Study: 11803077
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine (Twinrix) administered on days 0, 7, and 21
Study: 11803077
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of monovalent hepatitis A and B vaccines
Study: 17241248
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine (Twinrix)
Study: 10429000
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (I‐NO) therapy at doses of 1, 4, and 16 ppm.
Study: 10429000
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (I‐NO) therapy (pooled doses) for treatment failures.
Study: 10429000
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group for treatment failures.
Study: 25381629
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg/day)
Study: 15736915
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1.3 g EPA and 0.9 g DHA per day) from week 30 of gestation (FO(pregn/lact))
Study: 15736915
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1.3 g EPA and 0.9 g DHA per day) from week 30 of gestation (FO(pregn))
Study: 10883412
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 12.5 mg daily)
Study: 8472720
Drug: verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 120 mg t.i.d.
Study: 2436462
Drug: Thrombin method
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin method (5,000 units/5 cc. X 2)
Study: 19934280
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR combined with cognitive behavioral group therapy (CBGT) (group C)
Study: 15257187
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg) and Indapamide (0.625 mg)
Study: 9588696
Drug: Estradiol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (100 microg by patch)
Study: 9588696
Drug: Progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (100 mg i.m.)
Study: 8108665
Drug: Prednisolone 50
Normalized name: prednisolone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 50 mg per day for 14 days, then 25 mg per day for another 14 days.
Study: 8108665
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for the same time period (14 days of 50 mg, then 14 days of 25 mg).
Study: 2697953
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy using helium-neon, infrared, argon, and helium-cadmium lasers
Study: 163938
Drug: ABOB 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABOB 1% solution applied topically
Study: 25433580
Drug: Calcium Fructoborate
Normalized name: CALCIUM FRUCTOBORATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Fructoborate 112 mg/day (CFB-1)
Study: 25433580
Drug: Calcium Fructoborate
Normalized name: CALCIUM FRUCTOBORATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Fructoborate 56 mg/day (CFB-2)
Study: 23515980
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g each administered twice daily for 10 days)
Study: 23515980
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (pantoprazole 40 mg plus amoxicillin 1 g twice daily for 5 days followed by pantoprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg each administered twice daily for 5 days)
Study: 16961694
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg day(-1) micronized progesterone
Study: 16961694
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg day(-1) oestradiol
Study: 16961694
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of progesterone and oestradiol
Study: 16961694
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of hormone supplement
Study: 11729008
Drug: Combined psychotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psychotherapy and pharmacotherapy
Study: 11729008
Drug: One-person treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-person treatment model (psychiatrist conducts psychotherapy and prescribes medication)
Study: 9205763
Drug: ebrotidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ebrotidine (400 mg/day)
Study: 9205763
Drug: ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (300 mg/day in healing phase, 150 mg/day in follow-up phase)
Study: 8427866
Drug: Vessel wall
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vessel wall shear stress calculated using a validated finite‐difference model of the Navier‐Stokes' equation with a coronary flow rate of 8 ml/sec.
Study: 3629187
Drug: Aluminium-containing antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium-containing antacid
Study: 30348912
Drug: Traditional flushing
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional flushing method with 10 ml syringe of saline
Study: 16215308
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg/day
Study: 25015740
Drug: IORT as
Approvals — FDA: no, EMA: no, PMDA: no
Description: IORT as APBI treatment
Study: 25015740
Drug: IORT boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: IORT boost treatment
Study: 18936479
Drug: Full-dose reirradiation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose reirradiation combined with chemotherapy (RT arm)
Study: 15932528
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone eye drops four times daily (group A)
Study: 15932528
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone eye drops twice daily (group B)
Study: 12598253
Drug: Remifentanil combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil combined with ketamine at 50 or 100 ng/mL
Study: 12598253
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 2 ng/mL
Study: 1734901
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (MTX) at a mean weekly dosage of 10.2 mg
Study: 6524917
Drug: Moderate energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate energy supplement (0 g protein, 420 kcal)
Study: 6524917
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (14 g protein, 84 kcal)
Study: 21646823
Drug: Motivational Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motivational Intervention (MI) + Treatment as Usual (TAU)
Study: 11989841
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 microg/h after an initial bolus of 100 microg plus terlipressin 2 mg
Study: 10078672
Drug: Psychomotor test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychomotor test 60 min after remifentanil infusion
Study: 6834205
Drug: Related play
Approvals — FDA: no, EMA: no, PMDA: no
Description: Related play therapy
Study: 6834205
Drug: Unrelated play
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unrelated play therapy
Study: 6834205
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no preoperative preparation)
Study: 29424008
Drug: 0.7 mg
Normalized name: naloxone 0.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg granisetron
Study: 29424008
Drug: Granisetron groups
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron groups (1 mg and 0.7 mg)
Study: 29934199
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus standard care (10-14 sessions over 10 months)
Study: 26655732
Drug: Low-dose cariprazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cariprazine (1.5-4.5 mg/day)
Study: 26655732
Drug: High-dose cariprazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cariprazine (6-12 mg/day)
Study: 24613434
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk (FM) 80 mL/d
Study: 24613434
Drug: Non-fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fermented milk (NFM) 80 mL/d
Study: 20498097
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for low libido in women (specific interventions not detailed)
Study: 18799936
Drug: intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous immunoglobulin (IVIG, 1.0 g/kg/dose)
Study: 15955958
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of methylprednisolone (MP)
Study: 15955958
Drug: 2,000 mg
Normalized name: garlic 2,000 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 mg of methylprednisolone (MP)
Study: 12025911
Drug: Micronized purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized purified flavonoid fraction (MPFF) - 450 mg of micronized diosmin and 50 mg of flavonoids expressed in hesperidin for 6 months
Study: 8948610
Drug: Intralesional interferon-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional interferon-gamma (IFN-G) injections
Study: 1721887
Drug: Isovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolemic hemodilution over 6 weeks with hydroxyethyl starch solutions (PCV down to 35-32%)
Study: 1721887
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment of 75 mg of acetylsalicyclic acid daily
Study: 6751656
Drug: 100-g oral
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g oral glucose load after 3-hour exercise
Study: 27215976
Drug: Lurasidone adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone adjunctive therapy
Study: 31377382
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait training (G-EO System), 20 sessions of 45 minutes each.
Study: 27567973
Drug: Child‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child‐ and Family‐Focused Cognitive-Behavioral Therapy (CFF‐CBT)
Study: 17685676
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (medicine ball training)
Study: 17685676
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (control group with no medicine ball training)
Study: 10535235
Drug: Al‐Anon facilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al‐Anon facilitation therapy
Study: 7768073
Drug: Tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 200 mg and higher
Study: 7768073
Drug: Tolcapone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (5 to 800 mg)
Study: 2382605
Drug: Urokinase (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (3.0 million units over 30 minutes intravenously) with maximal antianginal therapy and intravenous heparin
Study: 31896118
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (160 IU)
Study: 24638884
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment for ADHD
Study: 24638884
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (behavior therapy and/or stimulant medication)
Study: 21592234
Drug: Alfuzosin 10mg
Normalized name: Alfuzosin 10mg Oral tablet, extended release
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfuzosin 10mg daily for 4 weeks and dologesic (paracetamol+dextropropoxyphene, four tablets daily on demand) for 2 weeks
Study: 19779491
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg valsartan (V group, n=22)
Study: 19779491
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg valsartan plus low-dose trichlormethiazide (1 mg) (V+D group, n=21)
Study: 10717350
Drug: DTP acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP acellular vaccines
Study: 10717350
Drug: DTP whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP whole cell vaccine
Study: 10717350
Drug: 4-5 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-5 years after the third dose
Study: 8741950
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance (50 mg PO daily)
Study: 8741950
Drug: Cocaine challenge
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine challenge doses (0, 12.5, 25, and 50 mg IV)
Study: 3903789
Drug: Flupenthixol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (0.5 to 2 mg a day)
Study: 3903789
Drug: Diazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2.5 to 10 mg a day)
Study: 3903789
Drug: Sulpiride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (100 to 200 mg a day)
Study: 30792342
Drug: Interdisciplinary model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary model of care (smoking cessation support, home medicines review, home-based pulmonary rehabilitation)
Study: 23918000
Drug: Electronic Urticaria
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic Urticaria Patient Daily Diary (eUPDD)
Study: 23918000
Drug: Paper Urticaria
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper Urticaria Patient Daily Diary (UPDD)
Study: 21757939
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g paracetamol i.v.
Study: 11343813
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac sodium i.m.
Study: 21757939
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lornoxicam i.v.
Study: 18835043
Drug: Aripiprazole (15‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15‐30 mg/day)
Study: 18835043
Drug: Lithium (900‐1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (900‐1500 mg/day)
Study: 9513824
Drug: 2-week course
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week course of amoxicillin and tinidazole for index children and siblings younger than 18; 2-week course of Colloidal Bismuth Subcytrate and tinidazole for parents and siblings over 18
Study: 7699213
Drug: LH‐RH analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH‐RH analogs treatment for Group 1 patients (P.A.H. < -1 SDS) for 2 years
Study: 7699213
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for Group 2 patients (P.A.H. > -1 SDS) for 2 years
Study: 2646988
Drug: Daily change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily change of povidone-iodine dressing
Study: 28199710
Drug: CBT‐I +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐I + antidepressant (AD; escitalopram)
Study: 28199710
Drug: CBT‐I +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐I + placebo pill
Study: 20406273
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits advising mothers about healthy feeding practices (monthly advice up to 6 months and then at 8, 10, and 12 months)
Study: 15930443
Drug: Fortified dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified dairy product containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), oleic acid, folic acid, and vitamins A, B‐6, D, and E, 500 mL/d
Study: 15930443
Drug: Semiskimmed milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiskimmed milk with added vitamins A and D, 500 mL/d
Study: 12885705
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g essential amino acids (EAA group)
Study: 12885705
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g balanced amino acids (BAA group)
Study: 3693871
Drug: Temazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (10 mg)
Study: 9086127
Drug: New cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cell culture-derived vaccinia virus vaccine administered intradermally
Study: 9086127
Drug: New cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cell culture-derived vaccinia virus vaccine administered intramuscularly
Study: 9086127
Drug: Licensed vaccinia
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccinia vaccine administered by scarification
Study: 7967338
Drug: Ticlopidine, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine, 500 mg/day
Study: 27049086
Drug: Wuzhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuzhi capsule (one capsule in the morning and evening for 3 weeks)
Study: 27049086
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Wuzhi capsule)